Evidence map›Paper›PMID 35978576›Full record

ArticleBio-protocol2022

Immunohistochemistry of Immune Cells and Cells Bound to

Kieran Adam, Adam Mor

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kieran AdamColumbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
Adam MorColumbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
Columbia University Irving Medical Center · US

Funding

Novel mechanisms regulating PD-1 signaling and functionR01AI125640 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Adam Mor · 2016 to 2026
$4.3M
PAG is a novel target in immunotherapyR01AI150597 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2020 to 2024
$2.7M
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockadeR21CA231277 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2019 to 2020
$361k
NCI NIH HHS R21 CA231277NIAID NIH HHS R01 AI125640NIAID NIH HHS R01 AI150597
6 · The paper itself

Abstract

Employing a novel mouse model of immune related adverse events (irAEs) induced by combination of anti-PD1 and anti-CTLA-4 antibodies, we visualized immune infiltration into the liver, lung, pancreas, and colon. Here, we describe the avidin-biotin conjugate (ABC) method used to stain T cells (CD4 and CD8), B cells (CD19), macrophages (F4/80), and cells bound by the

Indexed as

AntibodyCytotoxic T Lymphocyte Associated protein 4 (CTLA-4)Immune checkpoint blockadeImmune related Adverse Events (irAEs)ImmunohistochemistryMice modelsProgrammed cell Death protein 1 (PD-1)T cells

Identifiers

PMID35978576
PMCPMC9350918
OpenAlexW4286354706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.